Phase 3 clinical study of RZ358 underway in patients with congenital hyperinsulinism (cHI); topline results expected in mid-2025
Originally posted here:
Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update
Recommendation and review posted by G. Smith
